A phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone and oral azithromycin, a current … Positive results announced in largest pivotal phase 3 trial of a first-in-class oral antibiotic to treat uncomplicated gonorrhoea
Geneva, 19 October 2023—The Government of Japan has granted additional funding to the Global Antibiotic Research & Development Partnership (GARDP) to support its vital work … Japan government funding supports GARDP’s efforts to counter antibiotic resistance
Osaka (Japan), Chennai (India), Geneva (Switzerland), Boston (USA), 12 September 2023—A new agreement is poised to accelerate antibiotic access for tens of thousands of patients … Critical agreement paves way for new model to accelerate access to important antibiotics for serious bacterial infections
Geneva, 15 August 2023 – A new antibiotic treatment is now on track to receive final review by the US Food & Drug Administration (FDA). … Novel antibiotic treatment to become the first in the GARDP portfolio to be reviewed by US FDA for potential approval
The Global Antibiotic Research and Development Partnership (GARDP) has launched an observational study in India that will shed light on the management of antibiotic-resistant infections … GARDP launches new initiative to shed light on the management of antibiotic-resistant infections in Indian hospitals
Geneva and Bangalore, 27 July 2023 – The Global Antibiotic Research & Development Partnership (GARDP) is joining forces with Bugworks Research Inc. (Bugworks), an innovative clinical-stage … GARDP and Bugworks join forces to accelerate development of a novel antibiotic to treat serious bacterial infections
Geneva, 8 June 2023 – A global observational study, which involved more than 3,200 newborn babies suffering from sepsis in 19 hospitals in 11 countries, … Global study highlights deaths from neonatal sepsis and steps to improve treatment
Gonorrhoea is among the three most common sexually transmitted infections, affecting men and women worldwide. Global infection rates of gonorrhoea are increasing, with 82 million … GARDP and Innoviva Specialty Therapeutics announce completion of patient recruitment for registrational phase 3 gonorrhoea treatment trial
Geneva, 22 May 2023 – The UK government has renewed its support to GARDP by investing an additional £5 million in 2023/2024 to help develop … UK Government invests £5 million in GARDP to boost antibiotic development and access
Geneva, 22 May 2023 – An international clinical trial to evaluate much-needed new antibiotic combinations for newborn babies with sepsis has started in three public … Groundbreaking clinical trial to improve treatment for newborns with life-threatening sepsis gets underway in South Africa and Kenya